Lipoprotein(a) presents the proceedings of the International Symposium, held in Chicago, Illinois, on December 2–3, 1988. It discusses the different aspects of the research on lipoprotein(a), commonly referred to as Lp(a). It covers a wide range of topics, including comparative biology, metabolism, structure, epidemiology, and treatment. Comprised of 15 chapters, the book starts with an overview of the role of Lp(a) in atherosclerotic cardiovascular disease (ASCVD), followed by a discussion on recent findings and developments. It then considers the relationship between elevated plasma Lp(a) and the inherited risk factor for the development of coronary heart disease. The reader is also introduced to the various components of Lp(a), which include neutral lipids, polar lipids, apoprotein(a), and apoprotein B. Other chapters discuss the specific functions of apolipoproteins in plasma lipid metabolism, which determine the fate of the various lipoprotein particles in plasma. This book will be of benefit to cardiologists and medical practitioners.

Clinical Lipidology, a companion to Braunwald's Heart Disease, is designed to guide you through the ever-changing therapeutic management of patients with high cholesterol levels. From basic science to pathogenesis of atherothrombotic disease, to risk assessment and the latest therapy options, this medical reference book offers unparalleled coverage and expert guidance on lipidology in a straightforward, accessible, and user-friendly style. Get authoritative guidance from some of the foremost experts in the field. Easily access key content with help from treatment algorithms. Access options and evidence-based solutions for every type of patient scenario, as well as the latest clinical guidelines and clinically relevant evidence on risk assessment, special patient populations, and therapy, including recently approved and experimental therapies. Remain at the forefront of the cardiology field with up-to-date chapters on treatment guidelines; diet, exercise, and weight loss; pharmacologic therapies such as statins, omega-3 fatty acids, and combination therapy; evolving targets of therapy such as PCSK9 inhibition, CETP inhibition, and inflammation Prepare for special patient populations such as children and adolescents; women and the elderly; transplant recipients; HIV patients; and those with chronic renal disease, familial hypercholesterolemia, other severe hypercholesterolemias, diabetes, or other metabolic syndromes. Take advantage of a format that follows that of the well-known and internationally recognized Braunwald's Heart Disease. Expert Consult eBook version included with purchase.

Diabetes mellitus has become epidemic on a global scale, and millions of new cases are diagnosed every year. The epidemic of diabetes mellitus is expected to result in one of the steepest rises in human morbidity and mortality ever observed outside of wartime. Insulin resistance is a hallmark of pre-diabetes and type 2 diabetes mellitus, and is characterized by impaired insulin-signaling transduction. Authoritative and comprehensive, Lipoproteins in Diabetes Mellitus details the many changes wrought by insulin resistance and diabetes mellitus on lipid and lipoprotein metabolism. The book begins by summarizing the various techniques to measure lipoproteins and their subclasses. The mechanisms by which insulin resistance and diabetes mellitus increase risk for atherosclerosis, diabetic retinopathy, and diabetic nephropathy are then explored in detail. Finally, the effects of lifestyle modification and the results of clinical trials using established and investigational drugs are discussed. An invaluable contribution to the literature, Lipoproteins in Diabetes Mellitus is a comprehensive reference on the clinical and scientific aspects of lipoproteins in diabetes. It will have a long-lasting and significant effect on the medical management of people with diabetes.

Lipoprotein(a) [Lp(a)] is a unique lipoprotein that has emerged as an independent risk factor for cardiovascular vascular disease. Data from case control, epigenetic and mendelian randomization studies indicate that people with elevated Lp(a) have a two-fold to four-fold increased risk of cardiovascular events compared to people with low Lp(a) levels. Despite this risk, awareness of Lp(a) is still very low among health care providers. Even cardiologists often overlook Lp(a), in part because Lp(a) is not as well-understood as other risk factors and treatment options are still very limited. This book offers an authoritative and comprehensive overview of Lipoprotein(a). It provides an in-depth review of all aspects of Lp(a), from pathophysiology to metabolism. Chapters offer the reader a contemporary view of the important roles of Lp(a) as a risk factor for cardiovascular disease. In addition, this volume discusses the clinical implications of elevated Lp(a) and current and future therapies. Lipoprotein(a) is an essential resource for physicians, medical students, residents, fellows, and allied health professionals in lipidology, cardiology, endocrinology, pharmacotherapy, and health promotion and disease prevention.

In this rapidly evolving field of research, an enormous amount of new knowledge of lipoprotein structure, function and metabolism has emerged. The 1985 Nobel Prize-winning pioneering work of Brown and Goldstein on the LDL receptor has had a profound impact on developments in the field. This work is one of the many subjects reviewed in detail in this book. The volume begins with chapters on structure, then proceeds to analysis of lipid and lipoprotein dynamics, metabolism, function, genetics, and molecular biology. Lipoprotein genetics in molecular biology, the role of lipoprotein receptors, and Lp(a) - a topic underrepresented in volumes on lipoproteins, are another three such topics in an impressive volume. This work will mainly be of interest to researchers interested in lipid and lipoprotein structure and metabolism, but will also be of great value to clinical medicine and biology in general.